Peyronie's Disease


p
eyronie's disease forms fibrous plaques in the tunica albuginea causing erectile dysfunction, abnormal curvature and plaque formation in the penis. The disease affects mostly men between 40 to 60 years of age.

The basic mechanisms of inflammation contribute to the disease, with a combination of Vitamin E and colchicine showing some promise in delaying progression of the condition. Others report that a course of collagenase clostridium histolyticum may also help break down the excess collagen that causes Peyronies' disease.

However, one of the more promising treatments for Peyronie's disease has been supported by a clinical study in late 2014 styled "DETERMINING THE EFFECTS OF STEM CELL TREATMENT ON PEYRONIE'S DISEASE IN HUMANS."

The study evaluated the feasibility and effects of using Placental Matrix derived Mesenchymal Stem Cells in the treatment of Peyronie's disease. The Stem Cell Matrix consisted of a placental stem cell product that mixed mesenchymal stem cells with growth factors, cytokines, and an extracellular matrix to promote wound healing, angiogenesis, and tissue repair.

Each patient was evaluated for severity of the disease by using a penile ultrasound to measure the number and size of the Peyronie's plaques. Next, patients were then injected with 0.2 cc of Trimix to standardize data, evaluate peak systolic velocity (PSV) and angle of curvature.

On a separate visit, the Stem Cell Matrix was injected directly into the penis using a very small insulin sized needle. First, 1 cc of the Stem Cell Matrix was diluted with 2 cc of isotonic saline for a total of 3 cc. Up to 2.0 cc of diluted Stem Cell Matrix was then injected in and around the Peyronie's plaques. The remainder of the Stem Cell Matrix was then injected evenly into each corpora at the base of the penis.

An initial 5 patients enrolled in the study. At 6 weeks after treatment, peak systolic velocity increased in all patients (39%-81%). Using unpaired t-tests this was statistically significant (p<0.01).

All 5 patients demonstrated a reduction on ultrasound in the size of the plaques. The 4 patients with 3-month follow up had a 99%-100% reduction in plaque size. In total, there were 10 plaques between 5 people in the study, and 7 of those plaques completely disappeared on ultrasound.

In the 4 patients that had curvature caused by plaques, the angle showed a 10°-85° improvement, corresponding to a 14%-100% reduction in curvature. The reduction is 43%-100% in patients in the study for 3 months or more. All patients were happy with the treatment.

t
he clinical investigator reported that this study was possibly the first human study to ever report on the ability to use stem cells in the treatment of Peyronie's disease. Although the sample size was small, the results were statistically significant and very promising. For the results showed that the Stem Cell Matrix treatment was likely the most effective non-surgical treatment for Peyronie's disease today. The Stem Cell Matrix also increased the blood flow to the penis in a statistically significant amount.

This feasibility study implanted Stem Cell Matrix in humans patients diagnosed with Peyronies' disease. The Stem Cell Matrix is intended for further study in a multicenter clinical trial for validating these significant results.

A similar stem cell therapy protocol is now available to qualified patients.

Information Request Form


Your Name Phone Number E-mail Address Nearest Major City Your Message

* Required fields: name, e-mail, message, and reCaptcha

Medici Integrative Health & Surgery Center

Are You a Medici Integrative Health & Surgery Center Candidate?

To find out, please complete our Medici Integrative Health & Surgery Center Procedure Candidate Form.

Questions? Contact Us.